Russian Heart Failure Journal 2009year Metabolic parameters, markers of endothelial function and oxidative stress in geriatric patients with systolic and diastolic CHF

To access this material please log in or register

Register Authorize

Metabolic parameters, markers of endothelial function and oxidative stress in geriatric patients with systolic and diastolic CHF

Sukmanova I. A., Yakhontov D. A.



Urgency. Effects of age-related peculiarities of the cardiovascular system on key steps of the pathogenesis, course and prognosis of systolic and diastolic CHF are presently not studied sufficiently. Aim. To study parameters of carbohydrate, lipid and purine metabolism, major markers of endothelial function and oxidative stress and their interrelation with morpho-functional parameters of the heart in elderly patients with different types of CHF. Materials and methods. Study enrolled 127 men aged 60–75 years (mean age 67.4 ±0.3 years) assigned to 2 groups. Group 1 included 77 patients with diastolic CHF; group 2 consisted of 50 patients with systolic CHF. Control group included 30 healthy volunteers. Levels of pro- (IL-1β, TNF-α) and anti-inflammatory (IL-4) cytokines, the BNP fragment of brain natriuretic peptide (BNP), nitric oxide (NO), and markers of lipid peroxidation (LP) were measured. Results. Patients with both systolic and diastolic CHF had serious metabolic alterations, significant disorders of endothelial function and activation of oxidative stress markers. The observed disorders were aggravated by age-related changes in the cardiovascular system, which worsened both the course of disease and subsequent prognosis. Significantly higher levels of TNF-α, BNP fragment of BNP and uric acid in the group with systolic CHF indicated more severe disease and unfavorable prognosis in this category of patients.
  1. Haney S, Sur D, Xu Z. Diastolic Heart failure: a review and primary care perspective. J Am Board Fam Pract. 2005; 18 (3):189‑198.
  2. Алмазов В. А., Благосклонная Я. В., Шляхто Е. В., Красильникова Е. И. Метаболический сердечно-сосудистый синдром. – СПб.: СПбГМУ, 1999. – 204 с.
  3. Визир В. А., Березин А. Е. Роль иммунной воспалительной активации в формировании и прогрессировании сердечной недостаточности. Укранский Медицинский Журнал.1999; 6 (14):51–58.
  4. Ольбинская Л. И., Игнатенко С. Б. Роль системы цитокинов в патогенезе хронической сердечной недостаточности. Тер.архив. 2001; 71 (12):82–84.
  5. Blum A, Miller H. Role of cytokines in heart failure. Am Heart J. 1998; 135 (2 Pt 1):181‑186.
  6. Kapadia SR. Cytokines and heart failure. Cardiol Rev. 1999; 7 (4):196‑206.
  7. Finkel MS, Oddis CV, Jacob TD et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992; 257 (5068):387‑389.
  8. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in «cachectic» patients with severe chronic heart failure. Br Heart J. 1991; 66 (5):356‑358.
  9. Levine B, Kalman J, Mayer L et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323 (4):236‑241.
  10. Torre-Amione G, Kapadia S, Lee J et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996 Feb 15; 93 (4):704‑711.
  11. Ланкин В. З, Тихазе А. К., Беленков Ю. Н. Свободнорадикальные процессы при патологии сердечно-сосудистой системы. Кардиология. 2000; 40 (7):48–61.
  12. Schraufstatter IU, Hyslop PA, Jackson J, Cochrane CC. Oxidant injury of cells. Int J Tissue React. 1987; 9 (4):317‑324.
  13. Преображенский Д. В., Батыралиев Т. А., Шарошина И. А. Хроническая сердечная недостаточность у лиц пожилого и старческого возраста. – Москва: ЗАО «Альянс-ПРЕСИД», 2005 – 160с.
  14. Cline C. Heart failure in elderly. Tailoring Heart Failure Therapy. Eds. R. Willenheimer, K. Swedberg. – London: Martin Dunitz, 2003. – P. 15–30.
  15. Oxenham H, Sharpe N. Cardiovascular aging and heart failure. Eur J Heart Fail. 2003; 5 (4):427‑434.
  16. Терещенко С. Н., Павликова Е. П., Мерай И. А. Место мозгового натрийуретического пептида в диагностике сердечной недостаточности. Журнал сердечная недостаточность. 2003; 4 (2):103‑104.
  17. Yamaguchi H, Yoshida K, Sakata Y. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol. 2004; 43 (1):55–60.
  18. Гончаренко М. С. Метод оценки перекисного окисления липидов. Лаб. Дело. 1985; 1:60–61.
  19. Королюк М. А. Метод определения активности каталазы. Лаб. Дело. 1988; 1:16–18.

To access this material please log in or register

Register Authorize
Ru En